iNOs-IN-9
iNOs-IN-9 is a selective inducible nitric oxide synthase (iNOS) inhibitor with an IC50 of 82 nM against hiNOS. iNOs-IN-9 reduces cytokine-induced inflammatory responses and cell necrosis in inflammatory cell models. iNOs-IN-9 can be used for research related to psoriasis.
For research use only. We do not sell to patients.
- Formula: C16H13N5O3
- Molecular Weight:323.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
iNOS 82 nM (IC50) |
iNOs-IN-9 (Compound 10) (0.01-10 μM; 15 min preincubation, 30 min incubation at 37 °C) potently and selectively inhibits human iNOS with an IC50 of 82 nM, showing no significant inhibition of bovine eNOS at concentrations up to 10 μM and a selectivity ratio >116[1].
iNOs-IN-9 (10 μM; duration of cytokine stimulation) downregulates cytokine-induced inflammatory gene and membrane marker expression in primary human keratinocytes, with strong inhibitory effects on CXCL8, CCL2, CXCL10, ICAM-1, HLA-DR, and MHC class I[1].
iNOs-IN-9 (20 μM; 3 h) preserves histological integrity of healthy human skin explants and significantly reduces cytokine-induced inflammatory gene expression in this ex vivo model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HaCaT human keratinocytes (basal and pro-inflammatory conditions stimulated with TNF-α, IFN-γ, and IL-17)
-
Concentration:0.1-100 μM
-
Incubation Time:24 h, 48 h
-
Result:Did not alter HaCaT cell metabolic activity at any tested concentration after 24 or 48 h under basal conditions.
Slightly but significantly restored cell metabolic activity at concentrations of 50 and 100 μM after 24 h, and at concentrations of 20, 50, and 100 μM after 48 h under pro-inflammatory conditions, compared to cytokine-stimulated controls.
Decreased nitric oxide release in cytokine-stimulated HaCaT cells after 24 h.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:AB wild-type[1]
-
Dosage:1 μM, 10 μM, 20 μM, 30 μM
-
Administration:continuous immersion; duration dependent on exposure window (3-96 hpf or 48-120 hpf)
-
Result:Resulted in 100% survival with very low malformation rates not statistically different from controls when administered at 10 μM and 20 μM during 48-120 hpf exposure window.
Caused significant mortality and sublethal effects when administered at 10 μM during 3-96 hpf exposure window.
Resulted in 100% mortality and severe malformations including pericardial edema, scoliosis, craniofacial defects, and yolk deformation when administered at 20 μM and 30 μM during 3-96 hpf exposure window.
Chemical Information
-
Molecular Weight 323.31
-
Formula C16H13N5O3
-
SMILES
O=C(NC1=CC2=C(N=C1)C=CC=C2)CNC3=NC=CC=C3[N+]([O-])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz